Legal & General Group
PRQR icon

Legal & General Group’s ProQR Therapeutics PRQR Stock Holding History

Legal & General Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-55,917
Closed -$323K – 3377
2019
Q3 		$323K Sell
55,917
-11,025
-16% -$88K ﹤0.01% 2252
2019
Q2 		$610K Hold
66,942
– – ﹤0.01% 2101
2019
Q1 		$928K Hold
66,942
– – ﹤0.01% 1984
2018
Q4 		$1.06M Buy
+66,942
New +$1.23M ﹤0.01% 1881

Other funds holding PRQR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Legal & General Group's PRQR Position: Q4 2019 in Review

Legal & General Group sold out of ProQR Therapeutics (PRQR) in Q4 2019, closing a stake of 55,917 shares — an estimated $323K sold.

Legal & General Group first reported a position in PRQR in Q4 2018 and held it in 4 quarters. The position peaked at $1.06M in Q4 2018. 51 funds tracked by Wall St. Rank hold PRQR as of Q4 2019.

  • Legal & General Group reported no remaining ProQR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Legal & General Group sold 55,917 ProQR Therapeutics shares in Q4 2019, an estimated $323K.
  • Legal & General Group first reported a position in ProQR Therapeutics in Q4 2018 and held it in 4 quarters.
  • Legal & General Group's ProQR Therapeutics position peaked at $1.06M in Q4 2018.
  • 51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2019.

Based on Legal & General Group's 13F filing for Q4 2019, filed 13 Feb 2020.